Stocks · News reference

NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA

Aug 12, 2026, 12:03 PMBenzinga Newsdesk

— Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047)— Median overall survival of 26.09 months; 86.7% of patients alive at

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NTHI

Source: benzinga
Observed: Aug 12, 2026, 12:03 PM
Checked: Aug 12, 2026, 12:03 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

SEC EDGARAug 21, 2026, 6:58 PMSEC EDGAR
8-K/A filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filed: 2026-08-21 AccNo: 0001829126-26-009220 Size: 196 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
NTHI
BenzingaAug 14, 2026, 5:06 PMBenzinga Insights
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
AKAN BEAT CAPR DARE ETON
SEC EDGARAug 13, 2026, 9:21 PMSEC EDGAR
8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filed: 2026-08-13 AccNo: 0001829126-26-008773 Size: 326 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NTHI
BenzingaAug 12, 2026, 4:56 PMBenzinga Newsdesk
NeOnc shares are trading lower. The company announced topline results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.
NTHI

NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA

Connected Markets

Related Headlines

8-K/A filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)

12 Health Care Stocks Moving In Friday's Intraday Session

8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)

NeOnc shares are trading lower. The company announced topline results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.